SynaptiCOM.net is composed of three inter-dependent 'translational technology' initiatives.
Their respective specific aims focus on:
1) developing next-generation minimally-invasive nano-transponder technology (U.S. Patents 8,788,033, 9,302,114, and 9,802,050),
2) innovating technologies and techniques for visualizing and interfacing with epileptogenic networks, and
3) developing and deploying information technology-rich rural population health strategies.
Together our three initiatives strive to maximize 'effective connectivity from synapse to community'.
Our nano-sized technology initiative is filling the gap for energizing more robust brain stimulation therapy strategies. This novel nanotechnology remains on track for augmenting neuromodulation therapies and network remodeling for stabilizing medically-resistant epilepsies.
Our brain mapping initiative continues to evolve a suite of innovative human brain mapping techniques for visualizing the 'footprint' of epileptogenic brain circuits. The suite includes a cutting-edge intra-operative navigation platform for interfacing depth electrodes directly with epileptogenic networks. These neurovisualization software packages support the 'nanotech R&D' initiative. Both our brain mapping platforms and nanotechnology aim to facilitate establishing a new market and value network for impacting medically-resistant epilepsy.
The initiative was founded prior to the U.S. Affordable Care Act and now energized by it. Beginning in 2010, our platform was designed to deliver cutting-edge telehealth-based specialized healthcare. This mHealth-rich initiative serves as a testing platform for optimizing healthcare patterns of individuals living in rural communities throughout the U.S. This aim defines population health management (PHM).
Innovative PHM can meet the specialized healthcare needs of about 60 million people living in rural U.S. communities. A large proportion of these individuals live geographically distant from large regional medical centers. `
All three SynaptiCOM.net translational technology initiatives are energized by ongoing collaborative partners and sponsors. These include industry, academic institutions, rural community service organizations, county, state and federal grant resources, private foundations, and valued philanthropy.
The founder of SynaptiCOM.net, Marvin A. Rossi, MD, PhD, is a board-certified neurologist and epileptologist with a doctorate in Molecular Biophysics. Dr. Rossi has 30 years of translational research experience within regional NAEC-affiliated specialized epilepsy centers (predominantly the RUSH Epilepsy Center).